Kiran Mazumdar-Shaw outlines succession plan for Biocon, names niece as likely successor: Reports

Kiran Mazumdar-Shaw has initiated a succession roadmap for Biocon, indicating that her niece, Claire Mazumdar, is likely to eventually take over leadership of the biotechnology firm.

Following the reports, shares of Biocon were trading at ₹365.45 on the National Stock Exchange of India on Tuesday, up ₹4.85 or 1.34%.

In an interview with ‘Fortune India’, Mazumdar-Shaw said she viewed Claire as a natural successor, although no formal timeline has been set. She emphasised that any transition would be gradual.

“I am the sole owner of Biocon, and I need to make sure that I put it in good hands,” she said, adding that Claire had demonstrated the ability to run a company. In subsequent remarks and in an interview with Reuters, Mazumdar-Shaw clarified that she does not intend to step down immediately and would oversee a phased transition.

“I am not hanging up my boots anytime soon, but I want Claire to succeed me in a very phased manner,” she said, outlining a step-by-step progression that could see Claire move from a director-level role to vice-chair and eventually chair of the group.

As per Fortune India, Claire Mazumdar (37) is the founder and chief executive of Bicara Therapeutics, a biotech venture incubated by Biocon. The company was listed on the Nasdaq in 2024 with a valuation exceeding $800 million and now has a market capitalisation of over $1.6 billion, despite its lead cancer therapy still being in clinical trials.

She holds a degree in Biological Engineering from the Massachusetts Institute of Technology, an MBA from the Stanford Graduate School of Business, and a PhD in Cancer Biology from the Stanford School of Medicine. Prior to founding Bicara, she worked with Third Rock Ventures and Rheos Medicines.

Mazumdar-Shaw also indicated that Claire could draw on support from other members of the family, including her brother Eric Mazumdar, a faculty member at the California Institute of Technology specialising in artificial intelligence, and her husband Thomas Roberts, an oncologist at Massachusetts General Hospital.

The succession planning comes as Biocon undergoes a broader organisational overhaul, including the integration of its generics and biologics businesses, efforts to simplify its corporate structure, and measures to reduce debt.